A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

NCT00622336 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: CC-5013
DRUG: Lenalidomide

Sponsor

Celgene